Candidemia in a Pediatric Center and Importance of Central Venous Catheter Removal
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02088476 |
Recruitment Status :
Completed
First Posted : March 17, 2014
Last Update Posted : March 17, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Candidemia |
Study Type : | Observational |
Actual Enrollment : | 248 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Study Start Date : | January 2004 |
Actual Primary Completion Date : | December 2012 |
Actual Study Completion Date : | June 2013 |
Group/Cohort |
---|
Candidemia
Candidemia is defined as the presence of growth of any candida species in at least one blood culture obtained by either peripheral venipuncture or through an indwelling central venous catheter.
|
- Risk factors of candidemia [ Time Frame: up to 3 months ]The presence or absence of potential risk factors for candidemia such as an indwelling central venous catheter (CVC), use of antibiotics (administered for >72 hours), use of antifungals (administered for >24 hours), immunosuppressants, total parenteral nutrition (TPN), admission to the intensive care unit (ICU), mechanical ventilation, neutropenia, hypoalbuminemia and hypophosphatemia.
- Prognosis according to candida species [ Time Frame: up to 3 months ]Death which ensues within 30 days of the onset of candidemia with no apparent alternative cause is recognized as a candidemia-attributable mortality. Patients who died and survived were compared according to candida species (C.albicans, C. parapsilosis, C. tropicalis, C. sake, C.glabrata).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Presence of growth of any candida species in at least one blood culture
Exclusion Criteria:
- Febrile neutropenic patients who were using empirical antifungal agents

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02088476
Turkey | |
Hacettepe University Faculty of Medicine | |
Ankara, Turkey, 06100 |
Responsible Party: | Eda Karadag Oncel, MD, Hacettepe University Department of Pediatric Infectious Diseases, Hacettepe University |
ClinicalTrials.gov Identifier: | NCT02088476 |
Other Study ID Numbers: |
HUTF06 |
First Posted: | March 17, 2014 Key Record Dates |
Last Update Posted: | March 17, 2014 |
Last Verified: | March 2014 |
candidemia children mortality risk factors |
Candidemia Fungemia Sepsis Infection Candidiasis, Invasive Candidiasis |
Mycoses Invasive Fungal Infections Systemic Inflammatory Response Syndrome Inflammation Pathologic Processes |